Drug Approval | March 22, 2022
Merck’s Keytruda approved for fourth gynecologic cancer indication
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
Submissions for Ruminant Well-Being Awards and Gustav Rosenberger Memorial Fund grant open now
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Blood contains a mixture of exosomes secreted from nearly all tissues and cells, and exosomes from other tissues can mask changes caused by disease, making it difficult to detect the presence of biomarkers that reflect disease
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
The company plans to launch the product immediately
All of Us Research Program releases genomic data to researchers, combined with participant-generated data collected on Vibrent Health’s research platform
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
Subscribe To Our Newsletter & Stay Updated
